Platelet Resistance to Prostacyclin. Enhancement of the Antiaggregatory Effect of Prostacyclin by Pentoxifylline

Abstract

With regard to existence of high prostacyclin (PGI2) levels during atheromatosis and thrombus formation, resistance of platelets to prostacyclin and its analogues seems to play an important pathophysiologic key role for the clarifying of vasoocclusive phenomena. Platelet resistance to prostacyclin was studied in vitro and ex vivo in 160 atherosclerotic patients (assessed by objective diagnostic criteria) with and without thrombotic complications and in 50 controls. Prostacyclin resistance phenomena were more pronounced and frequent in patients with occlusive complications, the difference from controls being statistically significant. However, there was no significant difference between the controls and the nonthrombotic patient sample. The intraplatelet cAMP levels might be the metabolic basis of the PGI2 resistance phenomenon, because in the patient group, platelet cAMP levels were decreased by 50% after Ca2+ stimulation. Compared to controls beta-thromboglobulin and thromboxane B2 plasma levels were significantly increased (30 +/- 9 to 87 +/- 26 ng/ml and 9 +/- 5 to 54 +/- 21 pg/ml, respectively), confirming the hyperreactivity state of resistant platelets. From the therapeutic point of view, patients with resistant platelets require PGI2 doses that cause, however, increased side effects. We were able to demonstrate in vivo that IV pretreatment with pentoxifylline--a known stimulator of cAMP formation in platelets--followed by a simultaneous and continuous IV infusion of PGI2 + pentoxifylline, permitted us to reduce significantly the mean PGI2 doses needed for triggering an antiplatelet effect, without inducing side effects. In ex vivo studies, PGI2 resistant platelets of atherosclerotic patients pretreated with pentoxifylline showed normalized stimulation response, and platelet cAMP levels increased from 7.8 +/- 2.7 to 15.2 +/- 1.9 pmol/10(8) platelets.(ABSTRACT TRUNCATED AT 250 WORDS)

Pentoxifylline modulates meningeal inflammation in experimental bacterial meningitis

“…It improves microcirculation as a result of its rheologic effects on erythrocytes, platelets, and plasmatic components, resulting in a decrease of wholeblood viscosity (19,30). Recently, pentoxifylline was found to be of great benefit in different experimental sepsis models, including sepsis caused by gram-positive and gram-negative bacteria.…”

Anti‐platelet therapy: phosphodiesterase inhibitors

“…Pentoxifylline (3,7‐dimethyl‐1‐(5‐oxohexyl)‐xanthine), a vasoactive drug used in patients with intermittent claudication [13] and reported to reduce whole blood viscosity and to improve erythrocyte deformability, was shown to inhibit platelet aggregation in vitro in platelet‐rich plasma, but at concentrations higher than those attainable in vivo [14]. However, given that the platelet inhibitory effect was potentiated by PGI 2 , it was suggested that the in vivo antiplatelet activity could be stronger [15]; moreover, pentoxifylline was found to inhibit platelet aggregation in whole blood more effectively than in platelet‐rich plasma, due to the contribution of an adenosine uptake‐inhibitory effect on erythrocytes [16]. So far, there is no evidence that pentoxyfilline reduces ischaemic cardiovascular events [13].…”

The EU and the Negotiation of Global Development Norms: The Case of Aid Effectiveness

“…Expectations were high as can be seen by this NGO critique: 'the EU failed to leave a visible mark even on a field on which it has climbed the highest'. 79 Carbone sees the EU marginalized by the US, China and the developing countries themselves. 80 He contrasts the EU approach in Paris and Accra, where it had a clear agenda and plans for deliverables, with the approach in Busan where it could not speak with one voice 81 due to internal divisions and had few deliverables.…”